Clinical trial
A Phase I Open-label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of the FHND6091 in Subjects With Relapsed/Refractory Multiple Myeloma
NCT05271682 is registered in ClinicalTrials.gov with Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase I Open-label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of the FHND6091 in Subjects With Relapsed/Refractory Multiple Myeloma
- Lead sponsor
- Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd.
- Phase
- Phase 1
- Overall status
- Unknown status
- Start date
- December 22, 2021
- Completion date
- December 31, 2024
- Enrollment
- 40 (estimated)
- Sites
- 6
Conditions
As the registry lists them; a condition with its own page is linked.